Clinical trial
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive…
NCT00079092 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00079092 |
|---|---|
| Title | Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma |
| Official title | A Phase II Trial Of Thalidomide And Procarbazine In Adults With Recurrent/Progressive Gliomas |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | procarbazine hydrochloride, thalidomide |
| Enrollment | 18 |
| Start date | Jan 1, 2004 |
| Primary completion | Mar 21, 2006 |
| Completion | Mar 21, 2006 |
| First posted | Mar 9, 2004 |
| Last update posted | Sep 9, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: